NASDAQ: SEERSeer Inc Stock
$2.19+0.57 (+35.19%)
Updated Jul 6, 2026
SEER Price
$2.19
Fair Value Price
N/A
Market Cap
$120.41M
52 Week Low
$1.55
52 Week High
$2.41
P/E
-1.77x
P/B
0.5x
P/S
6.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.17M
Earnings
-$70.49M
Gross Margin
48.7%
Operating Margin
-464.06%
Profit Margin
-464.8%
Debt to Equity
0.13
Operating Cash Flow
-$48M
Beta
1.68
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
SEER Overview
Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials. The company markets its products exclusively for research applications, serving academic institutions, diverse life sciences and research laboratories, and biopharmaceutical and biotechnology enterprises. Notably, these offerings are intended for non-diagnostic and non-clinical purposes. Seer has established collaborative agreements with entities such as Discovery Life Sciences, LLC, and the Salk Institute for Biological Studies. Originally incorporated in 2017 as Seer Biosciences, Inc., the company adopted its current name, Seer, Inc., in July 2018. Its headquarters are situated in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SEER's potential to beat the market
- SEER doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important SEER news, forecast changes, insider trades & much more!
SEER News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SEER scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SEER is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SEER is good value based on its book value relative to its share price (0.5x), compared to the US Biotechnology industry average (5.58x)
P/B vs Industry Valuation
SEER is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SEER due diligence checks available for Premium users.
Valuation
SEER price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.77x
Industry
18.36x
Market
6.94x
SEER price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
5.58x
SEER is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SEER's financial health
Profit margin
Revenue
$2.8M
Net Income
-$16.8M
Profit Margin
-602.8%
SEER's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SEER's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$272.1M
Liabilities
$30.7M
Debt to equity
0.13
SEER's short-term assets ($181.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SEER's short-term assets ($181.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SEER's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SEER's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.4M
Investing
$18.1M
Financing
-$2.6M
SEER's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SEER vs Biotech Stocks
Seer Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.